312 related articles for article (PubMed ID: 38361756)
1. A review of the literature on the use of CRISPR/Cas9 gene therapy to treat hepatocellular carcinoma.
Amjad E; Pezzani R; Sokouti B
Oncol Res; 2024; 32(3):439-461. PubMed ID: 38361756
[TBL] [Abstract][Full Text] [Related]
2. Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment.
Wu X; Ma W; Mei C; Chen X; Yao Y; Liu Y; Qin X; Yuan Y
J Exp Clin Cancer Res; 2020 Jun; 39(1):97. PubMed ID: 32487115
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
[TBL] [Abstract][Full Text] [Related]
4. CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma.
Chen Y; Li L; Lan J; Cui Y; Rao X; Zhao J; Xing T; Ju G; Song G; Lou J; Liang J
Mol Cancer; 2022 Jan; 21(1):11. PubMed ID: 34983546
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
6. lncRNA- RP11-156p1.3, novel diagnostic and therapeutic targeting via CRISPR/Cas9 editing in hepatocellular carcinoma.
Ali HS; Boshra MS; El Meteini MS; Shafei AE; Matboli M
Genomics; 2020 Sep; 112(5):3306-3314. PubMed ID: 32544548
[TBL] [Abstract][Full Text] [Related]
7. Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma.
Kong H; Ju E; Yi K; Xu W; Lao YH; Cheng D; Zhang Q; Tao Y; Li M; Ding J
Adv Sci (Weinh); 2021 Dec; 8(24):e2102051. PubMed ID: 34665528
[TBL] [Abstract][Full Text] [Related]
8. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.
Huang S; Ma Z; Zhou Q; Wang A; Gong Y; Li Z; Wang S; Yan Q; Wang D; Hou B; Zhang C
Int J Biol Sci; 2022; 18(11):4357-4371. PubMed ID: 35864956
[No Abstract] [Full Text] [Related]
9. A Combinatorial CRISPR-Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment.
Xu F; Tong M; Tong CSW; Chan BKC; Chu HY; Wong TL; Fong JHC; Cheung MSH; Mak KH; Pardeshi L; Huang Y; Wong KH; Choi GCG; Ma S; Wong ASL
Cancer Res; 2021 Dec; 81(24):6219-6232. PubMed ID: 34666996
[TBL] [Abstract][Full Text] [Related]
10. Liver Cancer Gene Discovery Using Gene Targeting, Sleeping Beauty, and CRISPR/Cas9.
Kieckhaefer JE; Maina F; Wells RG; Wangensteen KJ
Semin Liver Dis; 2019 May; 39(2):261-274. PubMed ID: 30912094
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9 screens unravel miR-3689a-3p regulating sorafenib resistance in hepatocellular carcinoma via suppressing CCS/SOD1-dependent mitochondrial oxidative stress.
Lu Y; Chan YT; Wu J; Feng Z; Yuan H; Li Q; Xing T; Xu L; Zhang C; Tan HY; Lee TK; Feng Y; Wang N
Drug Resist Updat; 2023 Nov; 71():101015. PubMed ID: 37924725
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice.
Weber J; Öllinger R; Friedrich M; Ehmer U; Barenboim M; Steiger K; Heid I; Mueller S; Maresch R; Engleitner T; Gross N; Geumann U; Fu B; Segler A; Yuan D; Lange S; Strong A; de la Rosa J; Esposito I; Liu P; Cadiñanos J; Vassiliou GS; Schmid RM; Schneider G; Unger K; Yang F; Braren R; Heikenwälder M; Varela I; Saur D; Bradley A; Rad R
Proc Natl Acad Sci U S A; 2015 Nov; 112(45):13982-7. PubMed ID: 26508638
[TBL] [Abstract][Full Text] [Related]
13. Generation of genetically tailored porcine liver cancer cells by CRISPR/Cas9 editing.
Elkhadragy L; Regan MR; M Totura W; Goli KD; Patel S; Garcia K; Stewart M; Schook LB; Gaba RC; Schachtschneider KM
Biotechniques; 2021 Jan; 70(1):37-48. PubMed ID: 33222517
[TBL] [Abstract][Full Text] [Related]
14. Genome-Wide CRISPR/Cas9 Library Screening Revealed Dietary Restriction of Glutamine in Combination with Inhibition of Pyruvate Metabolism as Effective Liver Cancer Treatment.
Yang C; Lee D; Zhang MS; Tse AP; Wei L; Bao MH; Wong BP; Chan CY; Yuen VW; Chen Y; Wong CC
Adv Sci (Weinh); 2022 Dec; 9(34):e2202104. PubMed ID: 36310121
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus Vectors Expressing Eight Multiplex Guide RNAs of CRISPR/Cas9 Efficiently Disrupted Diverse Hepatitis B Virus Gene Derived from Heterogeneous Patient.
Kato Y; Tabata H; Sato K; Nakamura M; Saito I; Nakanishi T
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638909
[TBL] [Abstract][Full Text] [Related]
16. [Establishment of Cas9 stably expressed human hepatocellular carcinoma and cholangiocarcinoma cell lines].
Zuo CX; Bian XC; Yang ZL; Feng HL; Zhou FY; Liu YQ
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):572-579. PubMed ID: 30139026
[No Abstract] [Full Text] [Related]
17. A LIGHTFUL nanomedicine overcomes EGFR-mediated drug resistance for enhanced tyrosine-kinase-inhibitor-based hepatocellular carcinoma therapy.
Yi K; Kong H; Zheng C; Zhuo C; Jin Y; Zhong Q; Mintz RL; Ju E; Wang H; Lv S; Lao YH; Tao Y; Li M
Biomaterials; 2023 Nov; 302():122349. PubMed ID: 37844429
[TBL] [Abstract][Full Text] [Related]
18. TUBB4B is a novel therapeutic target in non-alcoholic fatty liver disease-associated hepatocellular carcinoma.
Yang Z; Gao S; Wong CC; Liu W; Chen H; Shang H; Wu ZY; Xu L; Zhang X; Wong N; Kuang M; Yu J
J Pathol; 2023 May; 260(1):71-83. PubMed ID: 36787097
[TBL] [Abstract][Full Text] [Related]
19. Charge-reversal nanocomolexes-based CRISPR/Cas9 delivery system for loss-of-function oncogene editing in hepatocellular carcinoma.
Nie JJ; Liu Y; Qi Y; Zhang N; Yu B; Chen DF; Yang M; Xu FJ
J Control Release; 2021 May; 333():362-373. PubMed ID: 33785418
[TBL] [Abstract][Full Text] [Related]
20. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
